Baird Medical Investment Holdings Debuts on Nasdaq

Baird Medical Investment Holdings Ltd. (BDMD) (“Baird Medical” or the “Company”), a prominent developer and provider of microwave ablation (MWA) medical devices in China, has recently expanded into the U.S. market following its receipt of FDA 510(k) clearances. The Company has successfully listed on the Nasdaq exchange, with shares trading under the ticker symbol “BDMD” as of October 2, 2024. This milestone marks the completion of its business combination and represents a significant step in its journey as a public entity. To commemorate the occasion, Co-Founder Wenyuan Wu, along with other executives, partners, and friends of the company, participated in ringing the Opening Bell.

Wenyuan Wu expressed, “Becoming a public company in the United States is both a critical juncture for us and signifies our shift toward addressing unmet needs in the market. Our technology benefits both patients and physicians by enabling safer, more efficient, and appealing procedures for thyroid care. We are excited to meet this pressing need as we expand our business.”

The Nasdaq listing aligns with the Company’s strategy to broaden its presence in the U.S. market, particularly following recent FDA clearance for its minimally invasive microwave ablation technology. This innovative approach presents a promising alternative to traditional thyroidectomy for patients with benign thyroid tumors, a procedure that sees approximately 150,000 cases performed in the U.S. each year.